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Abstract
The molecular mechanisms underlying chordoma pathogenesis are unknown. We therefore sought to identify novel
mutations to better understand chordoma biology and to potentially identify therapeutic targets. Given the relatively high
costs of whole genome sequencing, we performed a focused genetic analysis using matrix-assisted laser desorption/
ionization-time of flight mass spectrometer (Sequenom iPLEX genotyping). We tested 865 hotspot mutations in 111
oncogenes and selected tumor suppressor genes (OncoMap v. 3.0) of 45 human chordoma tumor samples. Of the analyzed
samples, seven were identified with at least one mutation. Six of these were from fresh frozen samples, and one was from a
paraffin embedded sample. These observations were validated using an independent platform using homogeneous mass
extend MALDI-TOF (Sequenom hME Genotyping). These genetic alterations include: ALK (A877S), CTNNB1 (T41A), NRAS
(Q61R), PIK3CA (E545K), PTEN (R130), CDKN2A (R58*), and SMARCB1 (R40*). This study reports on the largest comprehensive
mutational analysis of chordomas performed to date. To focus on mutations that have the greatest chance of clinical
relevance, we tested only oncogenes and tumor suppressor genes that have been previously implicated in the
tumorigenesis of more common malignancies. We identified rare genetic changes that may have functional significance to
the underlying biology and potential therapeutics for chordomas. Mutations in CDKN2A and PTEN occurred in areas of
chromosomal copy loss. When this data is paired with the studies showing 18 of 21 chordoma samples displaying copy loss
at the locus for CDKN2A, 17 of 21 chordoma samples displaying copy loss at PTEN, and 3 of 4 chordoma samples displaying
deletion at the SMARCB1 locus, we can infer that a loss of heterozygosity at these three loci may play a significant role in
chordoma pathogenesis.
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Introduction
Chordoma is an aggressive primary malignancy of the axial
skeleton that is thought to originate from notochordal tissue[1].
The majority of these tumors occur in either the base of the skull
(35%) or in the sacrum (50%), and these are typically managed
with surgery and/or radiation[2–10]. Their clinical behavior is
marked by slow growth and a predilection to recur despite surgical
resection. Most patients with recurrent chordoma and almost all
patients with metastasis will eventually die from this dis-
ease[11,12]. Unfortunately, there is no effective systemic agent
to control unresectable or metastatic chordoma and the develop-
ment of new treatments is limited by our poor understanding of its
biology[12–15].
The identification of driver mutations in malignancy, such as
EGFR-mutated lung cancers, c-Kit mutated gastrointestinal
stromal tumors, and ALK-translocated tumors, among others,
has dramatically changed the treatment landscape for these
diseases [15–20]. We hypothesize, therefore, that for a typically
chemoresistant tumor such as chordoma where there is no
effective systemic therapy, the identification of mutations in genes
for which there exist a therapeutic strategy can inform the
development of novel drugs. However, because of the rarity of
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patients with these tumors, comprehensive molecular understand-
ing of chordoma pathogenesis is currently incomplete.
Karyotype studies observed chordomas with loss at chromo-
some 1p and 3p and gains involving chromosomes 7q, 20, 5q, and
12q [21,22]. Mobley et al. identified a cohort of poorly
differentiated chordomas that lack SMARCB1/INI1 expression
[23]. Cytogenetic evaluation using FISH showed that 3 of the 4
samples had deletion at this locus. Gene sequencing did not reveal
any point mutations. Recently, Le et al. performed comparative
genomic hybridization on 21 chordoma tumor samples to show
frequent loss of chromosomal regions 9p21 and 10q23.3 [24].
They also genotyped for 56 point mutations occurring in 13 genes
commonly associated with cancer, including CDKN2A (located in
9p21) and PTEN (located in 10q23.3) but did not identify any
alterations in their cohort. We sought to expand on these
observations by analyzing 45 chordoma samples via high
throughput genotyping of cancer-associated genes known to play
an important role in cancer.
Methods
Ethics Statement
Institutional review board approval was obtained to retrospec-
tively study these tumor samples from the Partners Human
Research Committee, 116 Huntington Avenue, Suite 1002,
Boston, MA 02116. The protocol number is 2007P-002464. The
institutional review board waived the need to consent. Tumor
specimens were obtained from the clinical archives of Dr. Francis
Hornicek (Department of Orthopaedic Surgery, Massachusetts
General Hospital) and the Massachusetts General Hospital
Tissue Repository (http://www.massgeneral.org/cancer/research/
resourcelab.aspx?id= 31).
Chordoma tumor samples
Tumor specimens were obtained from the clinical archives of
Dr. Francis Hornicek (Department of Orthopaedic Surgery,
Massachusetts General Hospital) and the Massachusetts General
Hospital Tissue Repository (http://www.massgeneral.org/
cancer/research/resourcelab.aspx?id = 31).
Extraction of Genomic DNA
Extraction of DNA from chordoma tumor tissues and cell lines
were performed using QIAamp DNA Micro kit (Qiagen) as
previously described in prior publications [25]. The extraction was
carried out according to the manufacturer’s instructions. DNA was
preserved at 220uC until use.
Selection of Cancer Gene Mutations and OncoMap v3
Assay Design
Selection of cancer gene mutations for assay design and mass
spectrometric genotyping were performed as previously described
[25–27]. Multiple databases, including the Sanger Institute
COSMIC database, PubMed, and The Cancer Genome Atlas
(TCGA), were queried for known somatic oncogene and tumor
suppressor gene mutations. Mutations were ranked in importance
by frequency in cancers and across cancer subtypes, and genes
with existing therapeutic modifiers were preferentially selected.
Primers for PCR amplification and the extension probe were
designed using Sequenom MassARRAY Assay Design 3.0 and the
resulting DNA sequences were (1) queried in the dbSNP database
to avoid incorporation of SNPs during assay design, (2) confirmed
through a BLAST-like alignment tool (BLAT) and modified where
necessary to avoid pseudogene amplification[28], and (3) synthe-
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sized unmodified using standard purification (Integrated DNA
Technologies, Coralville, IA).
Mass Spectrometric Genotyping
Primers and probes were pooled and then validated on control
DNA derived from the CEPH panel of human HapMap DNAs
(Coriell Institute) as well as a panel of human cell lines with known
mutational status, as described previously[26]. Genomic DNA was
quantified using Quant-iT PicoGreen dsDNA Assay Kit (Invitro-
gen, Carlsbad, California), subjected to whole-genome amplifica-
tion (WGA) using Qiagen Repli-g kit, and a post-WGA cleanup
step was implemented using a Nucleofast Purification Kit
(Macherey-Nagel). Mass spectrometric genotyping using iPLEX
chemistries was performed as previously published [27].
Candidate mutations were further filtered by manual review
and selected for confirmation using multi-base extension homog-
enous Mass-Extend (hME) chemistry with plexing of#6 assays per
pool. Conditions for hME validation were consistent with the
methods described by MacConaill et al. 2009 [27].
Array Comparative Genomic Hybridization (CGH) Analysis
Array CGH using the Agilent 4x180k CGH + SNP microarray
(Santa Clara, CA) was previously described [24]. Copy number
aberration calls were made with a minimum regional absolute
average log base 2 ratio of 0.25 and minimum contiguous probe
count of 5. All array data were manually reviewed for subtle
changes.
Results
Characteristics of Clinical Tumor Samples
A total of 45 DNA samples were derived from 40 patients who
had undergone operative resections of their chordoma. Patient
date of surgery (DOS), age, sex, tumor location, recurrence, and
metastasis are catalogued in Table 1. 28 specimens were obtained
from fresh frozen tissue, and 17 were derived from FFPE blocks.
Genotype and CGH Analysis
Examples of the mass spectrometric readouts are shown in
Figure 1. Mutation results are catalogued alongside patient
characteristics in Table 1. The identified mutations include:
ALK (A877S), CTNNB1 (T41A) also known as b-Catenin, NRAS
(Q61R), PIK3CA (E545K), PTEN (R130), CDKN2A (R58*), and
SMARCB1 (R40*).
Among the 28 freshly frozen samples tested, 6 mutations were
identified. Of the 17 FFPE samples tested, only 1 mutation (in
Figure 1. Mass Spectrophotometry Plot: Observing a Mutation in SMARCB1. PCR products differ in mass depending on whether the probe
extension detects a cytosine (C) or thymine (T). The figure in the right shows mass spec plot of an allele in SMARCB1 displaying a peak at both C and
T. The left panel shows that most samples tested were homozygous with C, and 2 samples were heterozygous.
doi:10.1371/journal.pone.0101283.g001
High Throughput Genotyping of Chordoma
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Figure 2. Selected View of aCGH Analyses (Chromosomes 9 and 10) from Two Cases. X-axis measures location along chromosome 9 (Panel
A) or 10 (Panel B). Y-axis measures relative probe count. A: aCGH showing heterozyogous copy loss at CDKN2A; B: aCGH showing
heterozyogous copy loss at PTEN.
doi:10.1371/journal.pone.0101283.g002
High Throughput Genotyping of Chordoma
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ALK) was identified. Similar to our previously reported rates of
detecting similar frequency of mutations between freshly frozen
and paraffin embedded osteosarcoma tumor samples [25], there
appeared to be no difference in the rate of mutations in samples
that were freshly frozen when compared to the samples of FFPE
prepared (Fisher’s exact test, p = 0.22 two tails). Two samples
(samples #7 and 8 in Table 1), taken from the same patient at
different anatomic locations and surgical dates, each had the same
mutations in both SMARCB1 and CDKN2A. When we
performed CGH analysis on the samples with CDKN2A and
PTEN mutations, we observed copy number losses at respective
loci (Figure 2), demonstrating that these mutations occurred in
regions of chromosomal loss.
Discussion
Chordomas have been previously described to have chromo-
somal aberrations and are characterized by chromosomal gains
and losses at various regions throughout the genome
[21,22,24,29]. A comprehensive genome-wide survey for high-
yield mutations have not yet been performed across a large
collection of chordomas. Array comparative genomic hybridiza-
tion (aCGH) was used to analyze 21 chordoma tumor samples[14]
and observed large copy number losses involving chromosomes
1p, 3, 4, 9, 10, 13, 14, and 18 [24]. In that study, a focused analysis
of 11 cancer-related genes did not reveal any new mutations in
DNA sequence. Diaz et al. performed a whole-genome single-
nucleotide polymorphism microarray analysis of 21 clival chordo-
ma samples to confirm CGH findings by others that chromosome
3 aneuploidy and chromosome 9p deletion occurs (albeit less
frequently than in sacral chordomas)[29].
With current technology, whole-genome sequencing of large
collections of chordomas is costly and laborious. Thus, we aimed
to broaden our mutational screen while focusing only on those
genetic alterations that have been previously implicated as
tumorigenisis drivers in other tumor types with the overall goal
of identifying new mutations that could direct further research into
chordoma therapeutic discovery. Some of the mutations identified
in this study are in genes well-known for their role as tumor
suppressors, such as PTEN and CDKN2A. Interestingly, both of
these genes lie in chromosomal regions that were frequently found
to have copy number losses in the recent CGH array analysis
(9p21 for CDKN2A and 10q23.3 for PTEN) at a rate of.80% for
each. Therefore, we performed CGH in the samples containing
mutations in PTEN and CDKN2A and found chromosomal loss
at each loci in the respective samples. Interestingly, 33% of
samples tested in Le et al. collection found complete loss of both
copies of CDKN2A – arguing that either a point mutation at
CDKN2A or complete copy loss of CDKN2A can lead to LOH at
this locus [24]. We therefore infer that loss of heterozygosity
(LOH) at these loci can potentially be a tumorigenic event for the
development of chordoma.
SMARCB1 is a subunit of the ATP-dependent chromatin
remodeling complex SWI/SNF, a powerful epigenetic tumor
suppressor, which directly antagonizes the histone methyltransfer-
ase EZH2. Mutations in SWI/SNF members are increasingly
being recognized in malignancies where they are now thought by
some groups to be more common than inactivating mutations in
p53 [30,31]. SMARCB1 also regulates the cell-cycle by activating
CDKN2A, and its loss leads to upregulation of EZH2 a molecule
that is being targeted by several inhibitors that are currently
undergoing clinical testing [32–34]. SMARCB1 is known to be
disrupted in malignant rhabdoid tumors, round cell soft-tissue
sarcomas (most were a subset of tumors resembling extraskeletal
myxoid chondrosarcoma with rhabdoid features, epithelioid
sarcomas, and schwannomatosis [34–38].
These tumors, like chordomas, are groups of rare neoplasms for
which no effective therapy is known. Mobley et al. observed that in
poorly differentiated chordomas, expression of SMARCB1 is also
lacking. They used FISH to evaluate the SMARCB1 locus at
chromosome 22q and found deletion in 3 of 4 samples[38]. We
therefore also infer that when SMARCB1 mutations coincide in
areas of chromosomal loss, loss of heterozygosity can also be a
tumorigenic event.
Several of the mutations found in our study, such as ALK,
PIK3CA, and CTNNB1, each have inhibitors that are either
commercially available, such as the ALK inhibitor XALKORI
(crizotinib), or have multiple inhibitors currently under active
clinical development[39–44]. Observations such as ours suggest
the clinical utility of performing a genotype directed clinical trial to
test new kinase inhibitors in this disease population.
In conclusion, we observed chordomas with point mutations in
tumor suppressor genes in areas of frequent chromosomal loss and
in oncogenes with commercially available inhibitors. The former
suggests possible mechanisms for chordoma tumorigenesis, the
latter suggests possibilities for novel therapies. Further studies need
to be done in order to establish these genes as important
biomarkers or targets in chordoma. The ideal study would be a
complete genome sequencing effort involving many more chor-
doma samples. We hope that this initial sign of successful
genotyping in the largest collection of human chordoma tumor
samples to date may ignite enthusiasm to further investigations
into the molecular pathology of this disease that currently has no
effective medical therapy.
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